Roy Raj, Vinjamuri Saketh, Baskara Salian Rishabh, Hafeez Nosheen, Meenashi Sundaram Dakshin, Patel Tirath, Gudi Thulasi Ram, Vasavada Advait M
Internal Medicine, Gandhi Medical College and Hospital, Secunderabad, IND.
Internal Medicine, Kasturba Medical College, Manipal, IND.
Cureus. 2023 Jul 19;15(7):e42113. doi: 10.7759/cureus.42113. eCollection 2023 Jul.
Heart failure remains a leading cause of hospitalization and death, and presents a significant challenge for healthcare providers despite the advancements in its management. This umbrella review aimed to pool the results of meta-analyses on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in the treatment of heart failure patients. A literature search was done on five databases: PubMed, Cochrane Library, Scopus, Global Index Medicus, and Science Direct for articles with full texts available online. Meta-analyses of five or more randomized controlled trials (RCTs) were included; the assessment of multiple systematic reviews (AMSTAR) was used to assess the quality of included studies. A systematic search identified 10 relevant meta-analyses of RCTs, with primary analyses including outcome data from 171,556 heart failure patients. A pooled review showed that SGLT-2 inhibitors significantly reduced the risk of heart failure hospitalization, cardiovascular death, mortality, serious adverse events, and improved quality of life. SGLT-2 inhibitors are likely safe and effective in managing patients with heart failure especially considering the acute outcomes.
心力衰竭仍然是住院和死亡的主要原因，尽管在其管理方面取得了进展，但对医疗服务提供者来说仍是一项重大挑战。本综述旨在汇总关于使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂治疗心力衰竭患者的荟萃分析结果。对五个数据库进行了文献检索：PubMed、Cochrane图书馆、Scopus、全球医学索引和科学Direct，以查找可在线获取全文的文章。纳入了五项或更多随机对照试验（RCT）的荟萃分析；使用多项系统评价评估（AMSTAR）来评估纳入研究的质量。一项系统检索确定了10项相关的RCT荟萃分析，主要分析包括来自171556名心力衰竭患者的结局数据。一项汇总综述表明，SGLT-2抑制剂显著降低了心力衰竭住院、心血管死亡、全因死亡、严重不良事件的风险，并改善了生活质量。考虑到急性结局，SGLT-2抑制剂在管理心力衰竭患者方面可能是安全有效的。
